Valproic Acid to Boost Anti-EGFR in Colorectal Cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding valproic acid to standard anti-EGFR plus irinotecan can stop or reverse resistance in metastatic colorectal cancer. It is for patients who previously responded well to an anti-EGFR drug and then progressed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have metastatic colorectal cancer with normal RAS and BRAF genes (no mutations)
- You previously received an anti-EGFR drug (like panitumumab or cetuximab) and it worked well for at least 6 months, then you had another treatment after it stopped working
- You have not taken valproic acid or similar HDAC inhibitors before
- You are healthy enough for daily activities (ECOG score 0–1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (irinotecan liposomes, cetuximab, and vemurafenib) for people with advanced colorectal cancer that has a specific genetic change (BRAF V600E mutation) and did not respond to first treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of two drugs (regorafenib and sintilimab) plus electroacupuncture for people with advanced colorectal cancer that hasn't responded to standard treatments. The goal is to see if this triple therapy can help shrink tumors or slow the cancer's growth.
This study tests a new approach for people with a specific type of metastatic colorectal cancer that has stopped responding to initial treatments. It compares reusing a targeted drug combination (irinotecan plus cetuximab) versus a different chemotherapy plus a targeted drug (trifluridine/tipiracil plus bevacizumab) to see which works better for patients whose tumors have a certain genetic profile.
This trial tests whether adding an anti-EGFR drug to standard chemotherapy helps people with right-sided advanced colorectal cancer that has not had chemotherapy before. You need to have a specific gene pattern (no RAS mutation and high AREG/EREG) to join.
This trial tests a combination of two drugs, regorafenib and 5-FU with leucovorin, for people with colorectal cancer that has spread and has not responded to at least two previous treatments. The goal is to see if this new mix can help shrink or control the cancer.
This trial tests a combination of a targeted therapy pill (TKI) and an immunotherapy (PD-1 inhibitor) for people with advanced colorectal cancer that has stopped responding to standard treatments. It uses a blood test to tailor the treatment, aiming to be more effective with fewer side effects.
Hear when a new Colorectal Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.